[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-369154-105":59,"doc-detail-369154-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","proteomic-profiling-identifies-muscle-invasive-bladder-cancers-with-distinct-biology-and-responses-to-platinum-based-chemotherapy","Proteomic profiling identifies muscle-invasive bladder cancers with distinct biology and responses to platinum-based chemotherapy","","Proteomic profiling examines muscle-invasive bladder cancer before and after platinum-based neoadjuvant chemotherapy using archival formalin-fixed paraffin-embedded tissues. Four pre-treatment proteomic clusters with distinct biology and therapy response are identified and integrated with transcriptomic subtypes and immunohistochemistry. Post-treatment tumors show proteomic plasticity, increased extracellular matrix, and reduced keratinisation, with clusters enriched for druggable proteins. Intratumoural proteome heterogeneity before therapy predicts worse prognosis, suggesting protein-cluster biomarkers and therapeutic targets.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/proteomic-profiling-identifies-muscle-invasive-bladder-cancers-with-distinct-biology-and-responses-to-platinum-based-chemotherapy/369154/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/proteomic-profiling-identifies-muscle-invasive-bladder-cancers-with-distinct-biology-and-responses-to-platinum-based-chemotherapy/369154.png","ImageObject",300,407,{"name":92,"@type":93},"Eliana","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-01","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":34},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What data type and samples are used to study treatment response?","Question",{"text":112,"@type":113},"The study profiles the global proteome using archival formalin-fixed paraffin-embedded tissue collected pre- and post-neoadjuvant chemotherapy, analyzed by mass spectrometry.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How many proteomic clusters are identified before chemotherapy, and what is their significance?",{"text":117,"@type":113},"Four pre-neoadjuvant chemotherapy proteomic clusters are identified, each showing distinct biology and response patterns, and they are integrated with transcriptomic subtypes and immunohistochemistry.",{"name":119,"@type":110,"acceptedAnswer":120},"What post-chemotherapy proteomic changes are observed?",{"text":121,"@type":113},"After platinum-based neoadjuvant chemotherapy, tumors show proteomic plasticity linked to increased extracellular matrix and reduced keratinisation compared with pre-treatment, and some post-treatment clusters are enriched for druggable proteins.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},369154,1790216661,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":34,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},4398048949847,"https://ap-avatar.wpscdn.com/avatar/400002536579ef2da7f?_k=1778318612642679267","Article [https://doi.org/10.1038/s41467-024-55665-1](https://doi.org/10.1038/s41467-024-55665-1)  \nProteomic proﬁling identiﬁes muscleinvasive bladder cancers with distinct biology and responses to platinum-based chemotherapy  \nReceived: 15 April 2024  \nAccepted: 18 December 2024  \n\n| Published online: 01 February 2025 |\n| --- |\n| Check for updates |\n\nA. Contreras-Sanz 1,9 , G. L. Negri 2,9, M. J. Reike1,9, H. Z. Oo 1, J. M. Scurll1, S. E. Spencer 2, K. Nielsen2, K. Ikeda1, G. Wang 3, C. L. Jackson 4, S. Gupta 5, M. E. Roberts 1, D. M. Berman 4, R. Seiler1,6,7, G. B. Morin 2,8 &P. C. Black 1   \nPlatinum-based neoadjuvant chemotherapy prior to radical cystectomy is the preferred treatment for muscle-invasive bladder cancer despite modest survival beneﬁt and signiﬁcant associated toxicities. Here, we proﬁle the global proteome of muscle-invasive bladder cancers pre-and post-neoadjuvant chemotherapy treatment using archival formalin-ﬁxed parafﬁn-embedded tissue. We identify four pre-neoadjuvant chemotherapy proteomic clusters with distinct biology and response to therapy and integrate these with transcriptomic subtypes and immunohistochemistry. We observe proteomic plasticity post-neoadjuvant chemotherapy that is associated with increased extracellular matrix and reduced keratinisation compared to pre-neoadjuvant chemotherapy. Post-neoadjuvant chemotherapy clusters appear to be differentially enriched for druggable proteins. For example, MTOR and PARP are over-expressed at the protein level in tumours identiﬁed as neuronal-like. In addition, we determine that high intra-tumoural proteome heterogeneity in pre-neoadjuvant chemotherapy tissue is associated with worse prognosis. Our work highlights aspects of muscle-invasive bladder cancer biology associated with clinical outcomes and suggests biomarkers and therapeutic targets based on proteomic clusters.  \nBladder cancer (BC) is one of the most frequently diagnosed cancers1. It is responsible for over 570,000 new diagnoses and 212,000 deaths per year worldwide2. BC can be categorised as non-muscle-invasive (NMIBC; 75%) or muscle-invasive (MIBC; 25%). MIBC is an aggressive neoplasm that progresses to metastatic urothelial carcinoma (mUC) and death in approximately half of cases3.  \nMIBC is optimally treated with cisplatin-based neoadjuvant chemotherapy (NAC) followed by radical cystectomy (RC) in patients who are cisplatin-eligible, with an overall survival (OS) beneﬁt of 5–7% at 5 years. Approximately 40% of patients treated with NAC exhibit a major pathologic response (deﬁned as absence of muscle-invasive disease and nodal invasion) atthe time ofRC, and those with ypT0showed85%  \n1Department of Urologic Sciences, University of British Columbia, Vancouver, BC, Canada. 2Canada’s Michael Smith Genome Sciences Centre, BC Cancer Research Institute, University of British Columbia, Vancouver, BC, Canada. 3Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, BC, Canada. 4Department of Pathology and Molecular Medicine, Queen’s University, Kingston, ON, Canada. 5Department of Oncology, The Cleveland Clinic, Cleveland, OH, USA. 6Department of BioMedical Research, University of Bern, Bern, Switzerland. 7Department of Urology, Hospital Center Biel, Biel, Switzerland. 8Department of Medical Genetics, University of British Columbia, Vancouver, BC, Canada. 9These authors contributed equally: A.  \nContreras-Sanz, G. L. Negri, M. J. Reike. e-mail: [acontreras@prostatecentre.com](acontreras@prostatecentre.com); [peter.black@ubc.ca](peter.black@ubc.ca)  \n5-year survival3,4. Patients with residual MIBC are exposed to a risk of adverse effects from NAC and a delay in deﬁnitive local therapy without therapeutic beneﬁt5. To date, no validated molecular markers exist to guide therapeutic choices in MIBC patients. Identifying who will beneﬁt from NAC and subsequent RC therefore remains an active ﬁeld of research.  \nTranscriptomic characterisation of MIBC has deﬁned bi","cbCaiimYQgEOVpdX","https://ap.wps.com/l/cbCaiimYQgEOVpdX","pdf",4104219,18,"English","# Key Findings\n## Proteomic clustering and integration\n## Proteomic plasticity after treatment\n## Prognostic heterogeneity and biomarker potential\n# Clinical Background\n## Disease classification and outcomes\n## Standard treatment and response limitations\n# Rationale for Proteomic Analysis\n## Limits of transcriptomics\n## Need for FFPE proteogenomics approaches","[{\"question\":\"What data type and samples are used to study treatment response?\",\"answer\":\"The study profiles the global proteome using archival formalin-fixed paraffin-embedded tissue collected pre- and post-neoadjuvant chemotherapy, analyzed by mass spectrometry.\"},{\"question\":\"How many proteomic clusters are identified before chemotherapy, and what is their significance?\",\"answer\":\"Four pre-neoadjuvant chemotherapy proteomic clusters are identified, each showing distinct biology and response patterns, and they are integrated with transcriptomic subtypes and immunohistochemistry.\"},{\"question\":\"What post-chemotherapy proteomic changes are observed?\",\"answer\":\"After platinum-based neoadjuvant chemotherapy, tumors show proteomic plasticity linked to increased extracellular matrix and reduced keratinisation compared with pre-treatment, and some post-treatment clusters are enriched for druggable proteins.\"}]","Proteomic profiling identifies muscle-invasive bladder cancers with distinct biology and responses to platinum-based chemotherapy | PDF",1790181064,45,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/325f71c2f943f04088c3dfa4edb0c776.webp",983,1305,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/8d7262241ad6293bbc47b427903a60d9.webp",982,1304,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/79bc69c87281c73d849de148f3a46c9a.webp",981,1303,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/870af66658511ebc479d3f04186773a6.webp",980,1301]